Orbimed is an institutional investor (Healthcare Startups,) founded in 1989 and headquartered in New York City, United States. OrbiMed is a leading healthcare investment firm founded in 1989, managing over $5 billion in assets. The firm invests across pharmaceuticals, biotechnology, medical devices, healthcare services, and digital health. OrbiMed operates globally with offices in New York, San Francisco, Shanghai, Mumbai, and Tel Aviv, and has invested in 500+ healthcare companies. Venture capital fund focused on investing in healthcare industry. Invests in companies engaged in the discovery and development of biopharmaceutical products, medical technologies, medical devices, diagnostics, drug discovery tools, and healthcare information technology and services companies. Fund Philosophy: OrbiMed is a global investment firm that invests in companies engaged in the discovery and development of biopharmaceutical products, medical technologies, medical devices, diagnostics, drug discovery tools, and healthcare information technology and services companies. The firm believes the healthcare industry's powerful growth profile coupled with its magnitude and complexity create myriad investment opportunities. Assets Under Management (AUM): $5 billion+. Notable portfolio companies: Moderna (NASDAQ:MRNA), BioNTech (NASDAQ:BNTX), BeiGene (NASDAQ:BGNE), Grail (acq. by Illumina), 10x Genomics (NASDAQ:TXG), Synthego, Recursion Pharmaceuticals (NASDAQ:RXRX), SpringWorks Therapeutics (NASDAQ:SWTX), Passage Bio (NASDAQ:PASG), C4 Therapeutics (NASDAQ:CCCC).
- Stage
- Not disclosed
- HQ
- New York City, United States
- Founded
- 1989
- Website
- https://orbimed.com
- LinkedIn
- https://linkedin.com/company/orbimed-advisors
- Twitter
- https://twitter.com/orbimed
Institutional InvestorHealthcareHealthTechBiotechBiopharma
